Science News
from research organizations

Using tau imaging as diagnostic marker for Alzheimer disease

Date:
July 25, 2016
Source:
The JAMA Network Journals
Summary:
The accumulation of ?-Amyloid and tau proteins in the brain is hallmark pathology for Alzheimer disease. Recently developed positron emission tomography (PET) tracers, including [18F]-AV-1451, bind to tau in neurofibrillary tangles in the brain. So, could tau imaging become a diagnostic marker for Alzheimer disease and provide insights into the pathophysiology of the neurodegenerative disorder that destroys brain cells?
Share:
FULL STORY

The accumulation of β-Amyloid (Αβ) and tau proteins in the brain is hallmark pathology for Alzheimer disease. Recently developed positron emission tomography (PET) tracers, including [18F]-AV-1451, bind to tau in neurofibrillary tangles in the brain. So, could tau imaging become a diagnostic marker for Alzheimer disease and provide insights into the pathophysiology of the neurodegenerative disorder that destroys brain cells?

In a new article published online by JAMA Neurology, Beau M. Ances, M.D., Ph.D., of Washington University, St. Louis, and coauthors examined the usefulness of [18F]-AV-1451 PET imaging to stage AD and assess associations among Αβ, tau and volume loss in the brain.

The imaging study included 59 participants, the majority of whom were older men, who were cognitively normal or who had Alzheimer dementia.

The authors report that PET imaging using [18F]-AV-1451 distinguished participants with Alzheimer from those who were cognitively normal. Also, an elevated [18F]-AV-1451 binding was associated with volume loss in parts of the brain, according to the study.

"Overall, our work suggests that [18F]-AV-1451 is a valuable tool in tracking the continuum of the neurodegenerative process that ranges from the preclinical to clinical phase of AD," the article concludes.


Story Source:

Materials provided by The JAMA Network Journals. Note: Content may be edited for style and length.


Journal Reference:

  1. Liang Wang, Tammie L. Benzinger, Yi Su, Jon Christensen, Karl Friedrichsen, Patricia Aldea, Jonathan McConathy, Nigel J. Cairns, Anne M. Fagan, John C. Morris, Beau M. Ances. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. JAMA Neurology, 2016; DOI: 10.1001/jamaneurol.2016.2078

Cite This Page:

The JAMA Network Journals. "Using tau imaging as diagnostic marker for Alzheimer disease." ScienceDaily. ScienceDaily, 25 July 2016. <www.sciencedaily.com/releases/2016/07/160725121729.htm>.
The JAMA Network Journals. (2016, July 25). Using tau imaging as diagnostic marker for Alzheimer disease. ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2016/07/160725121729.htm
The JAMA Network Journals. "Using tau imaging as diagnostic marker for Alzheimer disease." ScienceDaily. www.sciencedaily.com/releases/2016/07/160725121729.htm (accessed May 26, 2017).

RELATED STORIES